The neuroprotective efficacy of MK-801 in focal cerebral ischemia varies with rat strain and vendor.
The present study was designed to evaluate whether the neuroprotective efficacy of MK-801 in focal cerebral ischemia was dependent on strain and/or vendor differences. MK-801 (0.12 mg/kg i.v. bolus followed by 0.108 mg/kg/h infusion or 0.60 mg/kg i.v. bolus followed by 0.540 mg/kg/h infusion) or saline was administered just after intraluminal middle cerebral artery occlusion. Administration of 0.540 mg/kg/h MK-801 provided strain/line-dependent neuroprotection in the following rank order: Simonsen Laboratories Sprague-Dawley rats > Simonsen Laboratories Wistar rats > Taconic Laboratories Sprague-Dawley rats. After 0.108 mg/kg/h MK-801 treatment, Simonsen Laboratories Wistar rats were the only strain/line that were significantly neuroprotected. These results indicate that the neuroprotective effect of an experimental drug may be influenced by rat strain and vendor differences.
Oliff
H S
HS
Department of Pharmacology, College of Medicine, University of California, Irvine 92717, USA.
Marek
P
P
Miyazaki
B
B
Weber
E
E
D000818:Animals; D000830:Animals, Laboratory; D001831:Body Temperature / Q000187:drug effects; D002545:Brain Ischemia / Q000188:drug therapy*; D002536:Cerebral Arteries / Q000601:surgery; D002540:Cerebral Cortex / Q000098:blood supply / Q000187:drug effects / Q000503:physiopathology; D016291:Dizocilpine Maleate / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D008026:Ligation; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar
D018696:Neuroprotective Agents; D016291:Dizocilpine Maleate